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Abstract
Purpose: Profound changes of the vasculature in tumors critically impact drug delivery and
therapy response. We aimed at developing a procedure to monitor morphological and functional
parameters of the vasculature in subcutaneous xenograft models commonly applied for therapy
testing by using probe-based confocal laser endomicroscopy.
Procedures: By monitoring various normal and diseased tissues, we established an experimen-
tal and analytical set-up to systematically analyze tracer extravasation from the microvascula-
ture. Application of the approach in two xenograft models (HCT-116 and SW620) was realized
consecutively throughout tumor growth.
Results: The incidence of dilated vessels increased with xenograft size in both models while
macromolecule extravasation and tracer accumulation in the tumor tissue, respectively, was
significantly reduced throughout growth. The development of dilated/ultradilated vessels
correlated with tracer extravasation only in the HCT-116 but not the SW620 model. The
underlying mechanisms are still ambiguous and discussed.
Conclusions: Our findings clearly indicate that both xenograft type and size matter for drug
delivery and therapy testing.
Key words: Macromolecule extravasation, Probe-based confocal fluorescence microscopy, In
vivo imaging, Tumor vasculature, Xenograft growth
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Introduction
Pathological conditions like inﬂammation, woundhealing, or cancer are characterized by the formation
of new vessels initiated by the production of proangiogenic
cytokines [1]. After tissue injury, permeabilizing factors
which are primarily stored in mast cells (e.g., histamine and
VEGF) are released and trigger a process called acute
vascular hyperpermeability (AVH)—a rapid inﬂux of an
exudate consisting mainly of plasma proteins which is self-
limited and attenuates within ∼30 min [2]. Angiogenesis is
terminated after healing resulting in healthy vasculature [3].
In contrast, tumors are often compared to chronic
inﬂammation and wounds that do not heal [4, 5]. Here,
exposure to angiogenic factors is not limited which causes
persistent angiogenesis with vessels that show profound
morphological and functional anomalies including chronic
vascular hyperpermeability (CVH) [2, 6]. It was reported
that macromolecules larger than 40 kDa extravasate in
solid tumors in contrast to normal tissues [7]. This
enhanced permeability and retention effect (EPR effect)
is the basis for the development of macromolecular
tumor-targeting drugs as they show prolonged plasma
half-life and higher tumor selectivity compared to conventional
chemotherapeutics [7, 8].
It is of utmost interest to gain deeper insight in the
pathophysiology of tumor vasculature and to develop
tools to better image and understand changes in vascular
function, particularly during therapy testing. The applica-
tion of conventional microscopy during an appointed time
course requires substantial numbers of animals [9], while
methods like MRI, CT, or optical ﬂuorescence imaging do
not reach spatial microscopic resolutions [10, 11]. Today,
diverse window chamber preparations are applied to
analyze vessels and vascular permeability via intravital
microscopy [12–14]. A disadvantage of these approaches
is their high invasiveness and the requirement of demand-
ing surgical procedures [15] as well as the limited tumor
size which makes them inappropriate for therapy testing.
Probe-based confocal laser endomicroscopy (pCLE;
Cellvizio® technology) offers the possibility for real-time
imaging of microvessels with minimal invasiveness and at
microscopic resolution [16–18]. Thereby, standard models
as used for therapy testing (e.g., subcutaneous xenografts
with diameters 90.5 cm) are becoming accessible for
in vivo microscopy.
Controversial results of studies on therapy testing in
animal models could be caused by methodical inconsis-
tencies [19]. For instance, there is no consensus about the
sizes of xenografts that enter treatment studies, although this
may critically impact the outcome because tumor character-
istics such as local microenvironment change throughout
growth. We were particularly interested in variations of
vascular morphology and macromolecule extravasation
during xenograft growth as those parameters can affect the
delivery and accumulation of putative anti-cancer drugs.
We applied pCLE to monitor vasculature in healthy and
diseased tissue in mouse models and developed a protocol
to visualize and estimate the extravasation and accumula-
tion of a ﬂuorescein isothiocyanate (FITC)-labeled dextran
tracer with the aim to distinguish acute and chronic
hyperpermeability. Based on our experimental set-up, we
for the ﬁrst time systematically studied morphology and
tracer permeation in two independent xenograft models
longitudinally throughout tumor growth.
Methods
C57BL/6 mice (12–16 weeks old) were used in the wound healing
experiments as described earlier in Peters et al. [20]. Experiments
on xenograft tumors were performed using 8–14-week-old female
NMRI-nu/nu mice for subcutaneous injection of HCT-116 and
SW620 colorectal cancer cells (ATCC). The animal facility and all
experiments were approved in accordance to institutional guidelines
and German animal welfare regulations.
Probe-based confocal laser endomicroscopy (pCLE, Leica
FCM1000; Leica Microsystems/Mauna Kea Technologies) was
applied on anesthetized mice using intravenously injected
FITC–dextrans (tail vein, 150 or 500 kDa, 3.5 mg per mouse;
Sigma-Aldrich) as tracers. The protocol to estimate tracer
extravasation is detailed in Fig. 1a and was used at three
tumor sizes longitudinally during xenograft growth. A leak
index, which relates the average extravascular ﬂuorescence
intensity IEn to the intravascular signal IVn, was calculated by
analyzing at least seven different ﬁelds of view (FOV) per
tumor and time point including ﬁve consecutive frames per
FOV. Vessels were segmented in the ﬁrst movie sequences
after tracer injection by iteratively segmenting each frame of
the movie (Fig. 1b) with custom-made software written in
MATLAB (The MathWorks). Due to lack of suitable FOVs and
loss of mice during xenograft growth, it was not possible to
include all tumors that entered the experiment in the analysis of
each size range. However, the results of the longitudinal studies
are obtained from the same cohort of xenograft tumors (n012
for HCT-116 and n023 for SW620).
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Detailed information on animal models, the pCLE system,
and the developed protocols including practical procedure, data
analysis, and image segmentation is given in the Electronic
Supplementary Material.
Results
Monitoring Healthy and Diseased Vessel
Networks In Vivo via pCLE
By injection of FITC–dextran (500 kDa), we monitored the
vascular morphology in different tissues in NMRI-nu/nu mice
via pCLE (Suppl. Fig. S1a). As revealed in tongue tissue, the
tracer distributed in the vasculature within a few seconds
(Video 1) and circulated in the blood. The movement of
unlabeled blood cells permits to follow the blood ﬂow in the
recorded movie sequences (Videos 2a and b).
A wound healing model in C57BL/6 mice was used to test
the applicability of pCLE for visualization of vascular recovery
in vivo. Clear changes in the proﬁle of the vasculature in wound
margins were observed (Suppl. Fig. S1b). At day 3 after
wounding, vessels were dilated and an increase in extravascular
signal indicated an enhanced vascular permeability. Seven days
after wound initiation, vessel morphology had somewhat
normalized, but hyperpermeability had not yet fully disappeared
as was the case at day 12 after wounding.
Fig. 1. Prerequisites to analyze macromolecule extravasation via pCLE. a Schematic illustration of the protocol to determine
tracer extravasation. To expose xenografts or muscles, a skin incision ( ) was required and directly followed by i.v. injection of
150 kDa FITC–dextran ( ) into the tail vein. One-minute sequences ( ) were recorded at defined time points after injection.
Areas which were recorded on five consecutive images were examined offline and the data was averaged for each FOV. At
least seven different FOVs ( ) were imaged, thus, a minimum of 35 frames (5 frames × 7 FOVs) were analyzed per time point and
animal. b Illustration of vessel segmentation for an individual frame. c Mean leak indices (IEn/IVn ± SD) of tongues of n08 NMRI-
nu/nu mice under normal conditions were estimated, see also Suppl. Fig. S5. d Intravascular signal (IVn, ± SD) in tongues
decreases slightly during monitoring. This clearance is independent from presence of a tumor (n04) and can be corrected for
[linear fit (n08), y0-0.9352x+100; r00.992].
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We also applied pCLE to subcutaneous xenograft tumor
models in NMRI-nu/nu mice. In general, a strikingly high
intertumoral heterogeneity within each model was observed
(Suppl. Fig. S1c). Intratumoral heterogeneity of vascular
networks was also high in some but not all xenografts
(Suppl. Fig. S1d), stressing the necessity to monitor
numerous FOVs for subsequent quantitative analyses. As
expected, tumor vessels showed a chaotic morphology, were
of highly variable size (length and diameter), and exhibited
tortuous courses without hierarchical order. Vessel constric-
tions or dead ends were seen in some tumors (Suppl. Fig. S3
and Video 3). Dilated vessels with diameters 950 μm were
frequent and possessed serpentine or linear nature with
different and altering rates of blood ﬂow (Videos 4a and b).
We compared the growth kinetics of xenografts that were
monitored twice throughout growth with pCLE with
respective untouched controls to exclude an impact of
anesthesia, skin incisions, tracer injections, and laser
illuminations on tumor growth. Fig. 2 documents that the
implemented protocol did not affect HCT-116 xenograft
growth. We also found that FITC–dextrans were no longer
detectable in the majority of tumors and normal tissues
(995 %) 3 days after injection. Vessel monitoring with the
technology can thus be realized repeatedly over a certain
time course.
Monitoring Extravasation in Normal Tissue
The 500 kDa FITC–dextran used in previous experiments to
visualize the vascular morphology infrequently extravasated,
e.g., after wounding, but seemed suboptimal for studying
tracer leakage. In contrast, 150 kDa FITC–dextran (3.5 mg
per mouse) was found to fulﬁll all requirements for both
vessel detection and tracking extravasation. Initially, healthy
tongue tissue under normal conditions without external
stimulus was analyzed for extravasation of i.v. injected
150 kDa FITC–dextran (Fig. 1c). The tracer did not
extravasate under those conditions as reﬂected by an
unchanged leak index (Fig. 1c and Suppl. Fig. S5). This
result was expected because the basal vascular permeability
(BVP) of normal microvessels is characterized by diffusion
of a plasma ﬁltrate with only little amount of larger
molecules. Because extravascular ﬂuorescence intensity
and image contrast remained stable, it was possible to apply
the vessel segmentation algorithm at all time points and to
monitor changes in vascular ﬂuorescence intensity IV during
the acquisition period. As expected, IV showed a slight
decrease due to tracer plasma clearance. This was indepen-
dent from the presence of a subcutaneous tumor (Fig. 1d).
The comparison of linear and exponential regressions
revealed overlapping functions for the time interval of
interest of ∼25 min (linear ﬁt y0−0.9352x+100, r00.992
and exponential ﬁt y0100e−0.0102x, r00.976, respective-
ly). According to the correlation coefﬁcients, the linear
equation was sufﬁcient to correct IVn in all further reported
measurements.
To verify if a strong increase in vascular permeability
caused by a particular event (AVH) can be visualized via
pCLE, tongues were pinched with the forceps directly
prior to the injection of 150 kDa FITC–dextran, and the
probe was then moved over the resulting lesion. The leak
index shown in Fig. 3a reﬂects the rapid inﬂux of FITC–
dextran into the surrounding tissue. This reaction was
restricted to the pinched regions and was already seen
during the ﬁrst time point in some FOVs. Therefore, it
was necessary to collect the images for calculation of
vascular fraction and IV from regions that were not
affected by the pinching. Another group of animals was
included whose tongues were pinched as described, but
tracer injection and vessel monitoring started 1 h later.
At this time point, no FITC–dextran extravasation was
detectable indicating the termination of the acute reaction
(Fig. 3a). The transient nature of this type of hyperpermeability
and its dependence on a stimulus substantiates that AVH
was induced.
Fig. 2. The pCLE imaging protocol does not affect HCT-116 tumor growth kinetics. Comparison of tumor volumes of HCT-116
xenografts in NMRI-nu/nu mice that were either imaged twice with pCLE during tumor growth or untouched (n05 tumors for
each group); 500 kDa a and 150 kDa b FITC–dextran was used as respective tracer molecule during acquisition. The range of
tumor volume where the measurements were applied is shaded in gray. The tumor volumes of the respective groups did not
significantly differ at any time point as was determined using two-sided Student's t test.
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Fig. 3. The proposed experimental protocol allows monitoring of AVH in normal tissues and CVH in xenografts. Representative
images of vasculature of tongues (a, n06), femur muscles (b, n07), and subcutaneous HCT-116 xenografts (c, n06) of NMRI-
nu/nu mice at different time points after 150 kDa FITC–dextran injection and the corresponding mean leak indices (IEn/IVn). Error
bars show the SD from n measurements. a Tongues were pinched and imaged either directly or one hour delayed. b, c Tracer
was injected directly after skin incision at the first site whereas the second site was injured and imaged 12 min later. *pG0.05,
two-sided Student's t test.
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To monitor extravasation of the tracer at the muscle site, a
small skin incision was necessary for direct access to the
tissue surface. As documented in Fig. 3b, rapid and massive
extravasation of the tracer occurred shortly after injection,
which evidently indicates an AVH reaction most reasonably
caused by the wounding. The second femur muscle of the
mice was included in the monitoring regime for approval.
The skin of the second leg was incised 12 min after FITC–
dextran injection and the measurement was thus delayed.
As expected, tracer extravasation started only after
wounding at the speciﬁc site and was completely
independent from the time point of FITC–dextran injec-
tion (Fig. 3b). The inducible characteristic of this reaction
and the healthy morphology of the vasculature thus reveal
the presence of AVH.
Chronic Vascular Hyperpermeability Detected
in Xenograft Tumors
We then utilized the protocol to monitor extravasation of
150 kDa FITC–dextran in our subcutaneous HCT-116
xenograft model. The images and leak index values
documented in Fig. 3c (ﬁrst site) indicate permeation of the
macromolecular tracer.
To further examine whether the hyperpermeability of
xenograft vessels is affected by the necessary skin incision
and may thus relate to response to injury, we applied the
same protocol as described for muscles by inducing and
monitoring xenografts in both hind limbs. Images taken
from the second tumor site (Fig. 3c, 13.5 min after tracer
injection) document that tracer extravasation already oc-
curred prior to the incision and ﬁrst measurement at this
location. The extravascular space shows a high ﬂuorescence
intensity which does not further increase as a function of
time implicating the absence of an acute reaction. The
resulting low-contrast images were not sufﬁcient to segment
tumor vessels and determine IV. Accordingly, exact IEn and
leak index values could not be determined. However, to gain
an impression, we used the mean values of vessel
fraction (1 − p) and IV of xenografts from the ﬁrst site
to estimate IB and IEn for the second site. In conclusion,
extravasation of the ﬂuorescent tracer had started directly
after injection and was independent of the time point of
wounding, reﬂecting the chronic hyperpermeable phenotype
(CVH) of tumor vasculature.
Vessel Morphology and Macromolecule
Extravasation Throughout Xenograft Growth
We repeatedly monitored vasculature and permeation as
therapeutically relevant parameters in HCT-116 xenografts
during growth at three different size ranges. With respect to
tracer extravasation, tumors exhibited higher leak indices at
smaller sizes (I and II) compared to the large volume (size
III, Fig. 4a). A signiﬁcant negative correlation between leak
index and tumor volume was observed (Fig. 4b). Neverthe-
less, after reaching size III all xenografts still showed
extravasation of the 150 kDa FITC–dextran as is reﬂected
by mean leak index values which were signiﬁcantly higher
compared to non-leaky vessels in normal tongue (Fig. 4a).
This indicates that vascular hyperpermeability was still
present.
Vascular fraction did not markedly differ between the
three tumor sizes (Table 1). However, dilated vessels with
diameters from 50 to 100 μm were found in tumors of all
sizes but with higher frequency in larger xenografts.
Excessively enlarged vessels with diameters over 100 μm
were not present in small tumors but common when
xenografts reached size III (Table 1). Tumors without dilated
and ultradilated vessels showed signiﬁcantly higher leak
index values (21.5 min after tracer injection) compared to
those with dilated vessels (3.95 ± 2.0 and 1.17 ± 0.7,
respectively, pG0.05, see also Suppl. Fig. S6). The data
indicate that xenograft size, incidence of dilated vessels, and
tracer permeation are related in the HCT-116 model.
To verify these ﬁndings, we studied a second subcutane-
ous xenograft model (SW620) with pCLE based on our
protocol. Again, measurements were performed longitudi-
nally at three size ranges. The vascular fraction in size I
SW620 xenografts was slightly lower than in subcutaneous
HCT-116 tumors. However, again no change in vascular
fraction throughout tumor growth was observed (Table 1).
Analogous to the HCT-116 model, SW620 tumors showed
tracer extravasation at every size range. Again, we observed
lower tracer leak indices when xenografts were larger (size II
and III) as compared to the ﬁrst measurement at size I
(Fig. 5a) and found a correlation between tracer leakage and
tumor volume in this xenograft model (Fig. 5b). The direct
comparison of the two xenograft models reveals signiﬁcant
variances in tracer extravasation as is particularly seen in
size II xenografts (170–265 mm3) with a mean leak index
differing by a factor of 2 (21.5 min after tracer injection,
pG0.05). Indeed, a signiﬁcant decrease in tracer extravasa-
tion is seen in the SW620 tumors only between sizes I and II
whereas the most prominent change in the HCT-116 model
occurs between size II and III xenografts.
Similar to the HCT-116 model, small SW620 xenografts
showed a lower frequency of dilated and ultradilated vessels
than after reaching size II and III, although there was almost
no difference between these larger sizes (Table 1). However,
not all size III SW620 xenografts had dilated vessels in the
examined FOVs and the incidence of ultradilated vessels
was under 40 % for both size II and size III tumors, as
compared to 62.5 % and 87.5 % of the respective HCT-116
xenografts. Accordingly, tumor size correlated with both
presence of dilated/ultradilated vessels and tracer leakage in
the SW620 model, but no direct relationship between the
two latter parameters was observed (Suppl. Fig. S6).
We further evaluated if the time interval between tumor
cell injection and xenograft formation affects tracer
extravasation. For this purpose, cell numbers ranging from
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500 to 1×105 SW620 cells were injected per site, and all
xenografts were monitored when they had reached size I,
i.e., between days 8 and 31. As documented in Fig. 5c,
the time to develop a xenograft did not alter the vascular
leak index. The reduction in tracer extravasation throughout
xenograft growth as well as the increase in dilated and
ultradilated vessels could thus be clearly attributed to tumor
size and may be a common phenomenon in subcutaneous
xenografts despite some cell and model type speciﬁc
modiﬁcations.
Fig. 4. HCT-116 xenografts show changes in extravasation of 150 kDa FITC–dextran throughout subcutaneous growth in
NMRI-nu/nu mice. a Representative images of vasculature of subcutaneous HCT-116 xenografts measured longitudinally
during growth at three different sizes. Twelve tumors were included in the experiment. Images show the same site of injection
0.5 and 10 min after tracer injection. The graph documents the kinetics of the mean leak index (IEn/IVn) with error bars showing
SDs from n08 (size I) and n05 (size II and III) tumors; leak indices significantly differ from normal tissue without tracer
extravasation (see Fig. 1c; *pG0.01, two-sided Student's t test). b The leak index values (21.5 min after tracer injection) correlate
negatively with the tumor volume (pG0.01 for f0n − 2). Error bars show the intratumoral SD of each measurement.
Table 1. Mean proportion of vascular fraction (±SD) in images taken from xenografts of different sizes 0.5 min after tracer injection and percentage of tumors
with dilated and ultradilated vessels
HCT-116 SW620
Size Ia Size IIb Size IIIc Size Ia Size IIb Size IIIc
Vascular 33.7 ± 4.6 % 38.5 ± 3.5 % 36.0 ± 5.2 % 31.3 ± 3.9 % 30.6 ± 5.5 % 31.6 ± 4.3 %
fraction (n06) (n05) (n05) (n015) (n011) (n08)
Tumors with Dilated vessels 62.5 % 87.5 % 100 % 60 % 81.8 % 87.5 %
(50-100 μm) (5/8) (7/8) (8/8) (9/15) (9/11) (7/8)
Ultradilated vessels
(9100 μm)
0 % 62.5 % 87.5 % 13.3 % 36.4 % 37.5 %
(0/8) (5/8) (7/8) (2/15) (4/11) (3/8)
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Discussion and Conclusion
pCLE permits real-time confocal recording with high
resolution and is only minimally invasive because of the
small diameters of the microprobes [16]. Thus, it is
applicable on standard disease models as shown in this
study. This is the ﬁrst demonstration of a consecutive
application of pCLE throughout xenograft growth which
remarkably reduced the number of animals.
The technology applied herein is suitable to monitor single
vessels, even though it was not possible to ﬁnd the exact same
FOV at different time points during measurement. Anyway,
due to the observed heterogeneity in the studied xenograft
models the analysis of only one small area in few tumors would
not reﬂect the characteristics of the vasculature. This is a
common limitation of microscopic methods, especially if ROIs
are manually positioned in every investigated frame [18].
Therefore, we aimed to average data from different FOVs for
each tissue by using a large ROI and mean values for
intravascular signal and vessel fraction to estimate the average
extravascular ﬂuorescence intensity. This could be realized by
moving the small-sized microprobe over the tissue surface,
thereby imaging up to 20 different FOVs (0 100 analyzed
frames) per tumor and time point. A vessel segmentation
algorithm was developed for image analysis and the leak index
of 150 kDa FITC–dextran was determined at deﬁned time
points after injection as an estimation of tracer permeation. This
may not reﬂect vessel permeability alone, as other parameters
also contribute to the amount of extravasated and accumulated
Fig. 5. Tracer extravasation in SW620 xenografts correlates with tumor volume but is independent of developmental period. a
Representative images of vasculature of subcutaneous SW620 xenografts measured longitudinally during growth at three
different sizes. Twenty-three tumors were included in the experiment. Images show the same site 0.5 and 10 min after tracer
injection. The graph documents the kinetics of the mean leak index (IEn/IVn) with error bars showing SDs from n015 (size I), n0
11 (size II), and n08 (size III) tumors. Leak indices significantly differ from normal tissue without tracer extravasation (*pG0.01,
two-sided Student's t test). b The leak index (21.5 min after tracer injection) correlate negatively with the tumor volume (pG0.01
for f0n − 2). c Leak index in size I SW620 xenografts (21.5 min after tracer injection) as a function of time after tumor cell
injection. Error bars in b and c show the intratumoral SD of each measurement.
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macromolecules. However, it gives an estimate of tracer
delivery to different tissues.
The presented protocol for pCLE could thus be applied to
monitor therapy responses as a function of drug delivery but
may also support studies on therapeutic strategies directed
towards tumor vasculature in vivo. Moreover, a multitude of
therapeutic antibodies are becoming promising tools in
cancer treatment, and it is possible to use ﬂuorochrome-
labeled variants in vivo during pCLE [21] and thereby pCLE
could provide information on their delivery to the target
tissue throughout therapy testing. It will also be useful to
investigate other pathophysiological aspects, e.g., the role of
the tumor micromilieu on the vasculature. There is accumu-
lating evidence, for example, that tumor-associated ﬁbro-
blasts contribute to the angiogenic switch in tumors [22], but
their genuine role in vivo remains unclear. We previously
described an accelerating effect of ﬁbroblasts on tumor
formation when co-injected with HCT-116 cells into NMRI-
nu/nu mice [23]. The developed protocols for pCLE now
offer the possibility to monitor vascular networks in such
co-injection xenograft models.
In the present study, we examined the extravasation of
150 kDa FITC–dextran of normal and tumor vasculature in
mice as a model for macromolecular tracer permeation.
Healthy microvessels of tongues under normal physiological
conditions were impermeable to the tracer as expected for
normal vessels possessing only BVP. This reveals that no
spurious effects are triggered by the measuring procedure
itself, e.g., vasodilation caused by phototoxicity or anaphy-
lactic reactions which were reported for higher doses of
injected FITC–dextran [24]. Upon induction, i.e., pinching
of the tongue or skin incision at the femur muscle site,
a strong tracer leakage was observed. In both cases,
hyperpermeability was acute (AVH) because it was termi-
nated within 60 min in tongues and depended on time of
injury in muscles. Here, the skin incision provoked a
massive inﬂux of FITC–dextran leading to mean leak index
values which were 9-fold higher compared to HCT-116
xenograft tissue. Accordingly, hyperpermeability of tumor
vessels in the xenograft model was a chronic process (CVH)
since it was independent of the time of skin incision. This
phenomenon, which was reported for many tumors [25, 26],
is presumably caused by the presence of proangiogenic and
permeabilizing factors triggering the EPR effect [8]. High
plasma levels of VEGF have for example been shown in
HCT-116 xenograft-bearing nude mice [27]. This may be
accompanied by basement membrane degradation, pericyte
detachment, and extensive vessel enlargement leading to
tortuous architecture of the vessel network and vascular
hyperpermeability [1, 28, 29].
We observed a high intra- and intertumoral heterogeneity
of the vascular morphology and grade of tracer permeation
in xenografts of both colorectal cell line models. This may
reﬂect diverse and heterogenic mechanisms of new vessel
formation which depend on unbalanced secretion of angio-
genic factors [3, 29, 30]. Interestingly, an increase in the
proportion of dilated vessels throughout tumor growth was
recognized. These are hypothesized to reﬂect so-called
mother vessels—less mature vessels with thin walls and
low pericyte coverage [3, 28, 29]. Extravasation of the
150 kDa FITC–dextran, however, was found to decrease
during xenograft growth which may demonstrate vascular
maturation or the development of vascular malformations
with muscular coat [3], both contradicting the mother vessel
theory. Furthermore, the incidence of dilated/ultradilated
vessels correlated with lower leak indices in the HCT-116
but not the SW620 model indicating that diverse mechanisms
are responsible for permeation changes during xenograft
growth.
The accumulation of macromolecules in tumors not only
depends on vascular permeability but is also affected by
interstitial ﬂuid pressure (IFP) and lymphatic abnormalities
[12, 30]. It seems reasonable that the higher ﬂuorescence
signal in smaller xenografts results from a strong accumu-
lation of ﬂuorescent dye in the interstitium which is
prevented by a high IFP in larger tumors. Indeed, it was
claimed that high IFP values are present in solid tumors [31]
and may lead to decreased uptake of plasma molecules and
high molecular weight drugs [32]. Therefore, the decreased
leak index values throughout tumor growth might not be due
to matured vessel characteristics but could instead be caused
by an increasing IFP despite vascular hyperpermeability.
Some previous reports imply that IFP increases with tumor
size [33], but others raise doubts that this is a general feature
[34] as the relationship of IFP and angiogenic abnormalities
was found to be very complex and depended on the tumor
model [14].
Our results on vascular morphology and extravasation
suggest that the selection of the xenograft model and its size
may among others be critical for drug delivery and thereby
affects outcome of therapy testing. Although there are
diverse explanations for tumor size-dependent alterations in
tracer leakage, the phenomenon itself may be common in
experimental tumors and has to be taken into account. It is
commonly agreed that orthotopic models are superior to
subcutaneous xenografts, but an obstacle is their restricted
accessibility for high-resolution imaging. The pCLE micro-
probes are ﬂexible and can thus also be used endoscopically,
so that some orthotopic models would become accessible for
(vessel) monitoring [35, 36]. The presented procedure can be
adapted to the respective requirements, e.g., we already
realized to monitor the vasculature in an orthotopically
grown rectal xenograft in a preliminary experiment (data not
shown). However, extended studies will be required to verify
if orthotopic tumors also show size-related modulations of
vascular structures and extravasation.
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